V
Vita S. Brawley
Researcher at Baylor College of Medicine
Publications - 19
Citations - 3332
Vita S. Brawley is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Antigen & Chimeric antigen receptor. The author has an hindex of 12, co-authored 19 publications receiving 2588 citations. Previous affiliations of Vita S. Brawley include Houston Methodist Hospital & Center for Cell and Gene Therapy.
Papers
More filters
Journal ArticleDOI
Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed,Vita S. Brawley,Meenakshi Hegde,Catherine Robertson,Alexia Ghazi,Claudia Gerken,Enli Liu,Olga Dakhova,Aidin Ashoori,Amanda Corder,Tara Gray,Meng Fen Wu,Hao Liu,John Hicks,Nino Rainusso,Gianpietro Dotti,Zhuyong Mei,Bambi Grilley,Adrian P. Gee,Cliona M. Rooney,Malcolm K. Brenner,Helen E. Heslop,Winfried S. Wels,Lisa L. Wang,Peter M. Anderson,Stephen Gottschalk +25 more
TL;DR: This first evaluation of the safety and efficacy of HER2-CAR T cells in patients with cancer shows the cells can persist for 6 weeks without evident toxicities, setting the stage for studies that combine Her2- CAR T cells with other immunomodulatory approaches to enhance their expansion and persistence.
Journal ArticleDOI
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Nabil Ahmed,Nabil Ahmed,Vita S. Brawley,Vita S. Brawley,Meenakshi Hegde,Meenakshi Hegde,Kevin Bielamowicz,Mamta Kalra,Daniel Landi,Daniel Landi,Catherine Robertson,Tara Gray,Oumar Diouf,Amanda Wakefield,Amanda Wakefield,Alexia Ghazi,Claudia Gerken,Claudia Gerken,Zhongzhen Yi,Zhongzhen Yi,Aidin Ashoori,Meng Fen Wu,Hao Liu,Cliona M. Rooney,Gianpietro Dotti,Adrian P. Gee,Adrian P. Gee,Jack Su,Yvonne Kew,David S. Baskin,Yi Jonathan Zhang,Pamela New,Bambi Grilley,Bambi Grilley,Milica Stojakovic,Milica Stojakovic,John Hicks,Suzanne Zein-Eldin Powell,Malcolm K. Brenner,Helen E. Heslop,Robert G. Grossman,Winfried S. Wels,Stephen Gottschalk +42 more
TL;DR: Investigation of whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether these cells have antiglioblastoma activity found them to be well tolerated.
Journal ArticleDOI
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Meenakshi Hegde,Malini Mukherjee,Malini Mukherjee,Zakaria Grada,Antonella Pignata,Daniel Landi,Shoba A. Navai,Amanda Wakefield,Kristen Fousek,Kevin Bielamowicz,Kevin Chow,Vita S. Brawley,Tiara T. Byrd,Simone Krebs,Stephen Gottschalk,Winfried S. Wels,Matthew L. Baker,Gianpietro Dotti,Maksim Mamonkin,Malcolm K. Brenner,Jordan S. Orange,Jordan S. Orange,Nabil Ahmed +22 more
TL;DR: TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2 in an augmented, bivalent immune synapse that enhances T cell functionality and reduces antigen escape.
Journal ArticleDOI
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada,Zakaria Grada,Meenakshi Hegde,Meenakshi Hegde,Tiara T. Byrd,Tiara T. Byrd,Donald R. Shaffer,Donald R. Shaffer,Alexia Ghazi,Alexia Ghazi,Vita S. Brawley,Vita S. Brawley,Amanda Corder,Amanda Corder,Kurt Schönfeld,Joachim Koch,Gianpietro Dotti,Gianpietro Dotti,Helen E. Heslop,Stephen Gottschalk,Winfried S. Wels,Matthew L. Baker,Nabil Ahmed,Nabil Ahmed +23 more
TL;DR: TanCAR as mentioned in this paper is a bispecific activation and targeting of T cells that can be used to increase the specificity of effector cells for malignant versus normal target cells, to offset antigen escape or to allow for targeting the tumor and its microenvironment.
Journal ArticleDOI
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde,Amanda Corder,Kevin Chow,Malini Mukherjee,Aidin Ashoori,Yvonne Kew,Yi Jonathan Zhang,David S. Baskin,Fatima A. Merchant,Vita S. Brawley,Tiara T. Byrd,Simone Krebs,Meng Fen Wu,Hao Liu,Helen E. Heslop,Stephen Gottachalk,Eric Yvon,Nabil Ahmed +17 more
TL;DR: Both HER2/IL-13Rα2-bispecific T cell products offset antigen escape, producing enhanced effector activity in vitro immunoassays and in an orthotopic xenogeneic murine model.